Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
Latest From Market Intelligence
Dermira aims to develop Roche's discontinued asthma antibody lebrikizumab in atopic dermatitis, in a deal worth $1.4 billion; Gilead entered CAR-T race with $11.9 billion buy of Kite Pharma. Biopharma funding was way up thanks to a $1.1 billion fundraise by Roivant Sciences.
In Vivo's editors pick September's most significant deals, including lucrative partnerships for Halozyme and the pursuit of Dimension Therapeutics. (Free article.)
With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.
When it comes to deal-making, In Vivo's editors have always been quick to single out transactions that we feel will spark trends or otherwise have a major impact on the life sciences industry. Below, an expandable timeline of the deals we chose as bellwethers for pharma and medtech in each year of this still-young century and what we said about them at the time. (Free article.)
AstraZeneca and Merck signed a broad targeted therapy and immuno-oncology alliance worth $8.5 billion; Japanese pharma Mitsubishi Tanabe boosted its neuroscience assets with the acquisition of NeuroDerm. Biopharma financing decreased from June, while device funding went up.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.